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1. Introduction 
Prenatal diagnosis, traditionally used as a synonymous for invasive fetal testing and 
evaluation of chromosomal constellation, presently encompasses many other issues like 
pedigree analyses, fetal risk assessment, population screening, genetic counseling and fetal 
diagnostic testing as well. Ultrasound guided chorionic villus samling (CVS), amniocentesis 
and, to a lesser extent, fetal blood sampling are used routinely in fetal medicine units. Other 
fetal tissue biopsies such as skin, liver and muscle biopsy are used only rarely. In this 
chapter we discuss the invasive diagnostic procedures in maternal fetal medicine with 
specific interest of showing the list of indications basic principles used for choosing the 
particular invasive technique, linkage of non invasive with invasive diagnostic procedures, 
precise description of techniques, list of complications and their prevention and 
management, all of these based on the recent scientific results and clinical experiences 
publicized in the available literature.  
2. Chorionic villus sampling 
The ability to sample and analyse  villus tissue was demonstrated in China, in 1975 
(Department of Obstetrics and Gynecology THoAIaSCA, 1975). Trying to develop a technique 
for fetal sex determination, Chinese inserted a thin catheter into the uterus guided only by the 
tactile sensation and small pieces of villi were aspirated. By today’s standards of ultrasonically 
guided invasive procedures this approach seems crude, but their diagnostic accuracy and low 
miscarriage rate demonstrated the feasibility of first-trimester sampling. Major advancements 
have occurred since that time in instrumentation, techniques for direct kariotyping, faster 
culturing of cells and in the molecular and biochemical assay of chorionic villi. Today in 
experienced centers, chorionic villus sampling (CVS) as a method of obtaining chorionic villi 
using transcervical or transabdominal approach, can be utilized as a primary prenatal 
diagnostic tool. Although CVS has the advantage of being carried out very early in pregnancy 
to the widespread amniocentesis, due to, more likely, the more technically demanding aspects 
of sampling, CVS has still not replaced amniocentesis in many centers. 
2.1 Timing and technique 
CVS is usually performed between 10 and 12 weeks of pregnancy. The risk and severity of 
limb deficiency appear to be associated with the timing of CVS: the risk before the end of 10 
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weeks  gestation  is higher than the risk from CVS done before that time. The upper limit for 
transcervical sampling has been suggested to be 12–13 weeks. Indeed, by the end of the first 
trimester, the gestational sac becomes attached to the decidual wall. Thereafter, any attempt 
to insert either a catheter or a biopsy forceps entails a higher risk of indenting and damaging 
the membranes .There are two paths for approaching placenta: through the maternal 
abdomen using a needle or through  the cervical canal by catheter or biopsy forceps. For 
transcervical  CVS, after ultrasound examination and determination of placental location, 
position of uterus and cervix is determined and a catheter path is mapped. (Vaughan & 
Rodeck,2001). The distal 3 to 5 cm of the sampling catheter is molded into a slightly curved 
shape and the catheter gently passed under ultrasound guidance through the cervix to the 
distal edge of the placenta under the ulatrasound visualization. The stylet is removed and a 
syringe with nutrient medium is attached. After obtaining negative pressure by a syringe 
the catheter is gently removed. In most cases chorionic villi are seen with naked eye in the 
syring (Dadelszen et al.,2005). For transabdominal approach the skin surface is treated with 
antiseptic solution. Trajectory of the needle should be chosen as much as parallel to the long 
axis of the trophoblast. The 20-gauge needle is inserted into chorionic villi (single needle 
technique). In some centers double needle technique is used. With this technique, 18-gauge 
needle is inserted into chorionic villi and the stylet is removed, then a smaller, 20-gauge 
needle with the aspirating syringe is inserted through this needle. Therefore if the sample is 
not adequate, sampling procedure with this smaller needle through 18-gauge needle can be 
repeated as necessary. Each technique (single or double needle) can be either free-hand or 
with needle-guide (alfirevic et al.,2003). 
2.2 Counseling before CVS 
Individualized counseling, by the obstetrician or an expert in genetics should always 
precede the procedure and support the couple in coming to a decision. Adequate time and 
personnel should be available to conduct a high-quality informed consent process in order 
to enhance the woman’s decision making about prenatal testing. Counseling patients before 
CVS  should emphasize some issues. First, the indication for invasive diagnosis in general 
and for CVS in particular. CVS is recommended for patients with very high risk of single 
gene disorder or chromosomal translocations in offspring. Although CVS should be also 
available to lower risk patients who wish karyotyping, the amniocentesis as an alternative 
should be offered. Second, specific data should be given to parents about failure, false-
negative and false-positive results of the procedure and the need of amniocentesis in cases 
with confined placental mosaicism which occurs in approximately 1-2%. At the end, the 
risks of CVS should be discussed, especially the risk of fetal loss. The risk of other 
complications is low and should not be discussed routinely, unless the patient asks. Written 
material about CVS might also be given to the couple. It is good clinical practice to obtain 
formal written consent for CVS before the procedure and it is mandatory in most centers. 
2.3 Indications 
Prenatal diagnosis in the first trimester has advantages over midtrimester diagnosis for a 
number of reasons. The first one is the advantage of an earlier procedure which brings relief 
to the patient when the results are normal and on the other hand allows an easier and more 
private pregnancy termination when necessary. Earliest time for having the chromosome 
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results is the 14th week with CVS and the 19th week with amniocentesis. First trimester 
abortion is followed by significantly lower rate of clinical complications. Speaking of 
emotional effect on patient, it is less stressful than labor induction and delivery at about 20 
weeks. Also, by that time maternal-fetal bonding is not clearly established and the 
pregnancy is generally not visible to the environment. Additionally, early diagnosis is 
essential when there is a need for in utero gene or stem cell therapy for the correction a 
genetic defect. The earliest applications of CVS were fetal sex determination and prenatal 
diagnosis of hemoglobinonopathies by DNA analysis ( Monni et al.,1993) Since then, 
advances in cytogenetic and DNA analysis techniques have remarkably expanded the 
number and types of genetic conditions detectable in the prenatal period. Currently, CVS is 
primarily indicated for chromosomal studies, DNA analysis of genetic disorders and 
prenatal diagnosis of inborn errors of metabolism. For chromosomal studies, the main 
indications for CVS are: maternal age over 35 years, previous pregnancy with a 
chromosomal abnormality or multiple anomalies, parents with proved chromosome 
translocations, inversions and aneuploidies, X-linked diseases, history of recurrent 
miscarriage, abnormal ultrasound scan and decrease or the absence of amniotic fluid  in the 
first trimester. The development of first-trimester screening methods for the detection of 
fetal chromosomal anomalies has increased the demand for CVS. In fact, although maternal-
related risk for fetal aneuploidy remains a common indication for CVS, the indication for 
CVS has evolved to become one of quick confirmation of an abnormal karyotype  whenever 
chromosomal abnormality is suspected based on ultrasound scan or biochemical screening 
in the first trimester. Less common indications for fetal karyotyping are multiple 
miscarriages and pregnancies after assisted reproductive techniques. First trimester 
ultrasound screening for Down syndrome can occasionally bring to light a number of fetal 
abnormalities. Holoprosencephaly, omphalocele, cystic hygroma, diaphragmatic hernia and 
megacystis are well known features of either aneuploidies or other genetic syndromes. 
When they are detected in the first trimester, CVS is indicated for fetal karyotyping or 
molecular studies. DNA-based diagnoses of single-gene disorders, such as cystic fibrosis, 
hemophilia, muscular dystrophy and hemoglobinopathies, continue to expand with 
advancing technologies and the discovery of the additional disease-causing  genes. Single 
gene disorders, which affect about 1% of livebirths, carry a high risk of recurrence and have 
unsatisfactory treatment so that prenatal diagnosis with termination of affected pregnancies 
is an important option for at-risk couples. Prenatal diagnosis of genetic disorders is based on 
the carrier detection procedures and genetic counseling of the couples at risk. Inborn errors 
of metabolism represent a vast group of disorders that are individually rare but together are 
a significant cause of human disease. Chorionic villi provide large amounts of metabolically 
active cytoplasm, therefore for many inherited metabolic diseases direct assay is possible, 
yielding diagnostic results within hours or a few days. Moreover, the amount of DNA 
obtained from a conventional sampling allows reliable analysis by recombinant DNA 
technologies. This is not the case with amniotic fluid cells, which provide too little DNA, 
which is frequently fragmented. Majority of these disease are very rare and new detection 
methods for specific disorders are constantly being reported so it is advisable to check with 
a specialists referral center on the current availability and preferred method for prenatal 
diagnosis. Some congenital infections such as rubella, toxoplasmosis, cytomegalovirus and 
parvovirus can also be detected by CVS. 
CVS in multiple pregnancies require more experience, ability and an accurate planning of 
the procedure. The procedure is not complicated in cases with clearly separated placentas 
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but it becomes a challenge in cases of fused or joined placentas, because in contrast to 
amniocentesis when one amniotic cavity can be marked with a dye, with CVS there is no 
technique to ensure that each sample has been obtained from a distinct placenta. To be sure 
to sample all fetuses one by one, and to reduce the risk of contamination, separate forceps 
and needles are inserted in succession and different samples are collected in close proximity 
to each cord insertion. A high level of expertise in technique of CVS is crucial. However, 
CVS can generally offer several technical advantages over midtrimester amniocentesis 
(Antsaklis et al.,2002). The easy evaluation of the membranes by ultrasound  makes both the 
prediction of chorionicity and amnionicity and the identification of the affected twin(s) more 
reliable, the use of rapid analytical methods makes substantial changes in the uterine 
topography very unlikely, and if same-sex dichorionic twins are diagnosed, DNA 
polymorphism markers may be easily checked to assure retrieval of villi from the individual 
placentas. In the hands of experienced operators, CVS has the same efficacy as mid-trimester 
amniocentesis for genetic diagnosis of multiple gestations: diagnostic error, probably due to 
incorrect sampling, is between 0,3% and 1,5%. Speaking of safety, carried out by expert 
physician, CVS appears at least as safe as amniocentesis (Brambati et al.,2001). Postprocedural 
loss rate after CVS in multiple pregnancies is somewhat higher than in singleton pregnancies 
but comparable to midtrimester amniocentesis. In cases where selective reduction is indicated 
the advantages of the first-trimester approach include a significantly lower emotional impact 
and a lower risk of clinical complications (Brambati et al.,2004) 
2.4 Laboratory considerations for chorionic villus sampling 
In the early development of CVS  there was a high rate of incorrect results due to maternal 
cell contamination and misinterpretation due to placental mosaicism. In the early 1990s the 
laboratory failure rate was 2,3%, which was significantly higher compared to amniocentesis. 
Nowadays CVS is considered to be a reliable method of prenatal diagnosis with a high rate 
of sucess and accuracy. Most centers report near 99% CVS sucess rate with only 1 % of the 
patients requiring a second diagnostic test ( amniocenteses or cordocenetsis) to clarify the 
results (Brun et al., 2003). Maternal cell contamination is the first cause of potential 
diagnostic errors which can occur after CVS.Obtained samples after CVS typically contain 
two cell lines: fetal i.e.placental villi and maternal i.e. decidua. It is posible that maternal cell 
line completely overgrow the culture and lead to incorect sex determination ans potentially 
to false- negative diagnosis. However, today, maternal cell contamination occurs in less then 
1% of cases and usually does not limit the possibilities of accurate diagnosis. Contamination 
of samples with significant amounts of maternal decidual tissue is almost always due to 
small sampling size. In experienced centers in which adequate quantities of villi are avilable, 
this problem has disappeared. The second major cause of potential diagnostic error 
associated with CVS is placental mosaicism (Kalousek et al.,2000). The rate of placental 
mosaicism in the frst trimester CVS is 1-2%. Although the fetus and placenta have a 
common ancestry, chorionic villus tissue will not always reflect fetal genotype. While 
initially placental mosaicism was considered as the main disadvantige of CVS in prenatal 
diagnosis, today it is an important marker for pregnancies at increased risk for growth 
retardation or genetic abnormalities. Two mechanisms can explain the occurance of 
placental mosaicism: mitotic error originally confined to the placenta and trisomic conceptus 
loosing of chromososme in the embryonic cell line. The most significant complication of 
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placental mosaicism is uniparental disomy which is the case when both chromosomes 
originate from the same parent (Kotzot et al.,2001). The clinical concequence of uniparental 
disomy occurs when the involved chromososme carries an imprinted gene in which 
expression is dependent on the patern of origin. For example, Prader-Willi syndrome may 
result from uniparental maternal disomy for chromosome 15. Because of this, all cases in 
which trisomy 15 is confined to the placenta should be evaluated for uniparental disomyy 
by amniotic fluid analysis. There is also evidence that placental mosaicism might alter 
placental function leading to the fetal growth restriction. This is especially relevant to 
chromosome 16 where placental trisomy affects growth of both uniparental and biparental 
disomy fetuses in a similar manner. A decision of termination of pregnancy should not be 
done on the basis  of mosaicism found on CVS. In such cases an amniocentesis should be 
offer to elucidate the extent of fetal involvement. Amniocentesis correlates perfectly with 
fetal genotype when mosaicism is limited to the direct preparation. When a mosaicism is 
observed in tissue culture, amniocentesis  is associated with a false negative rate of about 6% 
and mosaic fetuses were reported to be born after normal amniotic fluid analysis (Los et 
al.,2001). Follow-up may include fetal blood sampling or fetal skin biopsy. However, the 
predictive accuracy of these additional tests is still uncertain. 
2.5 Transcervical versus transabdominal chorionic villus sampling 
In most cases, operator or patient choice will determine the sampling route, but the choice of 
the route is usually decided on a case-by-case depending on placental site. Anterior and 
fundal placentas are usually easily accessed transabdominally while lower, posterior located 
placentas are more accessible transcervically. However, operators must be skilled in both 
methods. Both  techniques appear to be comparably efficient between 8 and 12 weeks, when 
the overall success rate after two sampling device insertions is considered to be very near to 
100% (Philip et al.,2004).This efficiency has been confirmed in three national randomized 
trials of transabdominal vs.transcervical CVS (Brambati et al.,1991; Jackson et al.,1992; 
Smidt-Jensen et al.,1992). Although the data appear to confirm that the two techniques are 
equally effective in obtaining adequate amounts of chorionic tissue, transabdominal 
needling entailed a significantly smaller proportion of repeated device insertions (3.3 vs. 
10.3%) and of low weight specimens (3.2 vs. 4.9%). Moreover, the complications due to 
undetected vaginal or cervical infection were much higher in the transcervical group. 
Additionally, speaking of safety, the Cochrane review showed that the transcervical CVS is 
more technically demanding than transabdominal CVS with more failures to obtain sample 
and more multiple insertions (Alfirevic et al.,2003). There are no differences in birth weight , 
gestational age at delivery, or congenital malformations with either method (Cederholm et 
al.,2003). Because of the specificity of the sampling route, transabdominal and transcervical 
sampling techniques are expected to have different types of contraindications. Vaginismus 
and stenotic or tortuous cervical canal, as well as myomas of the lower uterine segment, 
may severely hamper the introduction of either catheter or forceps. Active vaginal infection 
may also be an absolute contraindication to the cervical route. In the latter condition, vaginal 
and cervical culture and specific treatment do not seem sufficient to remove any risk of 
ascending infection. Transabdominal sampling may be relatively or absolutely 
contraindicated when obstacles such as intestines, large myomas or the gestational sac 
cannot be avoided. If olygohydramnios is present, transabdominal CVS may be the only 
approach available. 
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Transabdominal sampling, in our experience, has definitely become the method of choice, 
and our preference for this approach is based on the shorter learning time, the lower rate of 
immediate complications, the higher practicality and success rates at the first device 
insertion, the lower hazard of intrauterine infection, the opportunity to extend sampling 
beyond the first trimester, and the wider range of diagnostic indications.  
2.6 Complications 
The benefits of earlier diagnosis of fetal genetic abnormalities by chorionic villus sampling 
(CVS) or early amniocentesis must be set against higher risks of pregnancy loss and possibly 
diagnostic inaccuracies of these tests when compared with second trimester amniocentesis. 
The overall pregnancy loss rate following CVS has been reported in a number of relatively 
large clinical studies, and the values range from 2.2% to 5.4% (Odibo et al.,2008). The date 
used for determining the associated risks of fetal loss due to CVS are presented in the 
literature as case series with detailed outcome and comparative studies of CVS group versus 
amniocentesis and transabdominal versus transcervical CVS. Data evaluating the safety of 
CVS compares amniocentesis comes primarily from three collaborative reports ( Canadian 
Collaborative group, 1989; Medical Research Council, 1977; Rhoads et al.,1989). The results 
of Canadian Collaborative group demonstrated equivalent safety of CVS compared to 
midtrimester amniocentesis There was a 7,6% loss rate in the CVS group and a 7% loss rate 
in the amniocentesis group. A multicentric U.S. (Rhoads et al.,1989) study found slightly 
higher fetal loss rate following CVS (7,2%) compared to the one following midtrimester 
amniocentesis (5,7%). A prospective, randomized, collaborative comparison of more than 
3200 pregnancies, sponsored by the European Medical Council reported CVS having a 4,6% 
greater pregnancy loss rate than amniocenetesis.Based on the presented data, CVS is 
associated with a slightly increased risk of fetal loss when compared to amniocentesis. 
Noteworthy, that excluding the results of the MRC study, CVS is associated with no more 
then 1 % extra risk of fetal loss when compared to midtrimester amniocentesis. Also, the 
risks of fetal loss rate should not be compared between the studies since each study had its 
own criteria for total fetal loss (although most have described fetal loss  before 28 weeks 
gestation). Moreover, while some have included only cytogenetically normal fetuses, others 
have evaluated a mixed population. The risk of fetal loss after CVS can also be obtained 
from the studies comparing CVS with early amniocentesis (Caughey et al.,2006). Most of these 
studies point to a relatively small risk of fetal loss ( 2-3%) associated with CVS on the one hand 
and a significantly increased risk of fetal loss in the early amniocentesis gropu on the other 
hand. Logistic regression analysis of the procedure-related variables showed a significant 
association between fetal loss rate and maternal age, the lowest rates occurring in the youngest 
women (1.22%) and the highest in the women of 40 years and over, while gestational age 
affected the abortion rate only at 8 weeks (3.78%), no differences in the odds ratio being 
present at 9 to 12 weeks. Moreover, procedure related risk remained low later in pregnancy, 
and total fetal loss rates for CVS cases performed at 13–14 weeks and at least 15 weeks 
compared favorably with early and midtrimester amniocentesis respectively. Single-operator 
experience presents an estimated fetal loss after CVS of about 2-3%. Although, single operator 
experience shows that the results ( fetal loss rate) of early procedures are better in the hands of 
skilled operators, this remains controversial. Transabdominal CVS is considered by many to be 
safer than the transcervical approach.However, this observation is heavily influenced by the 
data from the Danish study (Smidt-Jansen,1992).Moreover no significant difference found 
www.intechopen.com
 
Invasive Prenatal Diagnosis 
 
7 
between those two approaches from two of three randomized trials comparing 
techniques.Based on these studies, as well as myny single center reports, we believe that the 
poor results from the Danish study ( where the Portex cannula was used) would not be 
repeated if the operators were equally good at the techniques being compared. Unfortunately, 
no study has randomly evaluated CVS versus non-sampled (with same risk) patients. 
Among early post-procedural complications, spotting within a few hours has been more 
frequently observed in patients undergoing transcervical rather than transabdominal CVS 
(Brambati et al.1991). Other sequelae due to injury to the placental circulation include retro-
placental hematomas and subchorionic hemorrhage. Significant amniotic fluid leakage after 
CVS is about 2-4 times less frequent when compared to early amniocentesis.  
Localized peritonitis immediately after sampling occurs in very few cases, and only after 
transabdominal sampling, with an overall rate of 0.04%. Intrauterine infection (acute 
chorionamnionitis) should be considered a potential, although very rare, complication of 
transcervical CVS, having been reported in 0.1–0.5% of cases, and in some large series no 
cases at all were observed (Paz et al.,2001). However, there is some concern about the role of 
less serious infection in women who experience fetal loss after transcervical CVS. Because 
transcervical CVS involves passage of a cannula or forceps through the cervical canal from 
the perineum and vagina, microbial colonization and infection, with consequent morbidity 
for both mother and fetus, may result (Cederholm et al.,2003). 
Feto-maternal hemorrhage following CVS has been demonstrated by a significant increase 
in maternal serum a-fetoprotein in 40–72% of cases, and in 6–18% of these the amount of 
blood transfused was calculated to exceed 0.1ml. Fetal hemorrhage should therefore be 
capable of initiating an immune response in RhD-negative women bearing an RhD-positive 
fetus. Moreover, an association between maternal serum a-fetoprotein increase and 
frequency of spontaneous fetal death has been suggested for the cases with the highest 
maternal serum a-fetoprotein levels (Mariona et al.,1986). 
In general, the rate of fetal abnormalities after CVS is not different than in general 
population. Several case reports and cohort studies in the early 1990s have suggested a 
possible association between  CVS and a cluster of limb defects and oromandibular 
hypogenesis. However, these findings were not repeated in other studies. The background 
risk of limb reduction defects (LRD) in the general population is low and varies between 1.6 
and 4/10000. In an evaluation of CVS safety presented by WHO, LRD cases were observed 
in 5.3/10000. The possible mechanisms of LRD following CVS are unknown. However, 
there are three principal theories: 
1. Vascular disruption caused by hemodynamic disturbances, vasoactive peptides or 
embolism 
2. Amnion puncture with subsequent compression and entanglement of the fetus. 
3. Immunological mechanisms causing increased apoptotic cell death 
It is speculated that technical aspects of the procedure may have a bearing on the amount of 
placental trauma associated with the sampling procedure and the risk of limb deficiency. 
However, the rarity of limb deficiency following CVS means that none of the existing trials 
have the power to clarify the effect of technical factors on the risk. It also remains unresolved 
whether the risk of limb deficiency differs for transabbominal versus transcervical sampling ( 
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Froster et al., 1996). Given the weight of current evidence supporting an association between 
early sampling and limb deficiency, it would be unethical to conduct a trial to investigate this 
prospectively. 
No increased frequency of perinatal complications, i.e. preterm birth, small-for-dates 
neonates, perinatal mortality and congenital malformations, have been observed both in 
randomized and clinical control studies (MRC Working Party, 1992). 
3. Amniocentesis 
Amniocentesis is the invasive diagnostic procedure by which amniotic fluid is aspirated 
from pregnant uterus using transabdominal approach. This method was first performed as 
therapeutic procedure more than 100 years ago for decompression of polyhydramnios. 
Amniocentesis became a diagnostic procedure in 1950s when Bevis first used amniotic fluid 
for measurement of bilirubin concetration and prediction of the severity of Rhesus 
immunisation. Today amniocentesis is a significant diagnostic tool for prenatal detection of 
chromosomal as well as metabolic disorder. Tests performed on fetal cells found in the 
sample can reveal the presence of many types of genetic disorders, thus allowing doctors 
and prospective parents to make important decisions about early treatment and intervention 
(Wilson, 2005). 
3.1 Timing and technique 
For karyotyping  amniocentesis is generally performed between 15 and 18 weeks of 
gestation with results usually available within three weeks. At this time, the amount of fluid 
is adequate (approximately 150ml), and the ratio of viable to nonviable cells is greatest. With  
the current technology amniocentesis is technically possible from 8 weeks of gestation  but 
this is not usually recommended because there appears to be an increased risk of 
miscarriage when done at this time (Allen & Wilson,2006). The advantage of early 
amniocentesis and speedy results lies in the extra time for decision making if a problem is 
detected. Potential treatment of the fetus can begin earlier. Important, also, is the fact that 
elective abortions are safer and less controversial the earlier they are performed. For 
assessment of the fetal lung maturity the amniocentesis can be used until term (Hanson  et 
al.,1990). Before the procedure, genetic couceling is mandatory and a detailed family history 
should be obtained. The parents should be informed about the complications and limitations 
of the procedure same as for CVS. After genetic counseling, a "level two" ultrasound is then 
done to check for any signs of fetal abnormalities, to check the fetal viability, to determine 
the position of the fetus and of the placenta, to examine closely the main fetal structures, and 
to double check the gestational age (Hanson  et al.,1990). Ultrasound is used  also to 
determine the best location for placing the needle-a pocket of substantial amniotic fluid well 
away from the baby and umbilical cord. When amniocentesis  first came into use, they were 
done "blind" (without continuous ultrasound guidance during the procedure), and this 
resulted in a number of disastrous outcomes, including occasional cases of horrifying fetal 
damage and death(Gratacos et al.,2000) .Modern amniocentesis is done with continuous 
ultrasound and is much less dangerous. For the amniocentesis, the mother lies flat on her 
back on a table. Iodine solution is swabbed onto her belly in order to cleanse the area 
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thoroughly, and sterile drapes are placed around the area. After  an appropriate sampling 
path has been chosen , a 20 to 22-gauge needle is introduced into a pocket of amniotic fluid 
free of fetal parts and a umbilical cord. The pocket should be large enough to allow 
advancement of the needle tip through the free-floating amniotic membrane that  may 
occasionally obstruct the flow of fluid. The first 2ml of amniotic fluid are discarded to 
reduce the risk of contamination  of  the sample with maternal cells which could 
occasionally lead to false-negative diagnosis. The amount of  withdrawn amniotic  fluid 
should not exceed 20 to 30ml (Blessed et al.,2001).There is confirmed relationship between 
higher fetal loss and aspiration of 40ml of amniotic fluid and more. Continuous ultrasound 
during an amniocentesis allows the doctor to see a constant view of the needle's path, the 
location of fetus and to identify uterine contractions that occasionally retract the needle tip 
back into the myometrium. If the fetus moves near the needle's path at any point, the doctor 
can then reposition the needle, or if necessary, withdraw the needle and try again in a 
different location. Continuous ultrasound has eliminated a great deal of the risk formerly 
associated with amniocentesis (Johnson  al.,1999). The procedure should be performed 
either free-hand or with the needle guide. The free-hand  technique allows easier 
manipulation  of  the needle if the position of the  target is altered by a fetal  movement or 
uterine contraction. Alternatively, a needle guide allows more certain  ascertainment of the 
needle entry point and a more precise entry determination of the sampling path. A needle 
guide technique is helpful for obese patients, in cases of oligohydramnios  and  for  
relatively inexperienced sonographer (Welch et al.,2006). After the fluid sample is taken, the 
doctor immediately  checks the viability of the fetus. Both uterine and maternal abdominal 
wall puncture sites should be observed for bleeding and anti-D should be given to Rh 
negative women. In experienced hands  and after 11 completed weeks of gestation the pure 
amniotic fluid aspiration has a success rate of 100%. If the initial attempt to obtain fluid is 
unsuccessful, a second attempt in another location should be performed after reevaluation 
of the fetal and placental positions. If unsuccessful after two attempts, the patient should be 
rescheduled in several days. The technique of early amniocentesis is similar to 
amniocentesis performed at later gestational ages. However, in the first trimester there are 
two sacs, the amniotic cavity and the extra-embryonic coelome. The incomplete fusion of the 
amnion and chorion in early gestation may result in tenting of the membranes, which may 
necessitate more needle insertions. It is important to distinguish the two sacs 
ultrasonographically at the time of the amniocentesis, as the fluid in the extraembryonic 
coelome is jelly-like, difficult to aspirate, and has a different alpha-fetoprotein concentration 
than amniotic fluid. Retrieval of fluid from this sac should be avoided, as it will only rarely 
produce enough cells to allow a cytogenetic diagnosis (Sundberg  et al.,1991). In order to 
assess whether amniotic fluid has been retrieved from both sacs in twin pregnancies, a 
marker (a dye or a biochemical substance) may be injected into the first sac. When the 
second sac is punctured, the absence of the marker in the amniotic fluid indicates that both 
sacs have been sampled. However, real-time ultrasound allows visually guided amniotic 
fluid sampling from both sacs, thus making dye-injection obsolete (Pijpers et al.,1988). 
Whether amniocentesis in twin pregnancies should be performed by using one or two 
needle insertions remains to be shown. A single needle insertion could reduce the abortion 
risk, but may on the other hand create the problems of amniotic band syndrome or a mono-
amniotic twin pregnancy, or give rise to cytogenetic problems (Millaire et al.,2006).  
www.intechopen.com
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
10
3.2 Indications 
Since the mid-1970s, amniocentesis has been used routinely to test for Down syndrome by 
far the most common, nonhereditary, genetic birth defect, affecting about one in every 1,000 
babies. By 1997, approximately 800 different diagnostic tests were available, most of them 
for hereditary genetic disorders such as Tay-Sachs disease, sickle cell anemia, hemophilia, 
muscular dystrophy and cystic fibrosis (Summers et al.,2007). 
Amniocentesis is recommended for women who will be older than 35 on their due-date. It is 
also recommended for women who have already borne children with birth defects, or when 
either of the parents has a family history of a birth defect for which a diagnostic test is 
available. Another reason for the procedure is to confirm indications of Down syndrome 
and certain other defects which may have shown up previously during routine maternal 
blood screening (Fergal  et al.,2005). The risk of bearing a child with a nonhereditary genetic 
defect such as Down syndrome is directly related to a woman's age—the older the woman, 
the greater the risk. Thirty-five is the recommended age to begin amniocentesis  testing 
because that is the age at which the risk of carrying a fetus with such a defect roughly equals 
the risk of miscarriage caused by the procedure-about one in 200. At age 25, the risk of 
giving birth to a child with this type of defect is about one in 1,400; by age 45 it increases to 
about one in 20. Nearly half of all pregnant women over 35 in the United States undergo 
amniocentesis and many younger women also decide to have the procedure. Notably, some 
75% of all Down syndrome infants born in the United States each year are to women 
younger than 35 (Jacobson et al.,2004). 
One of the most common reasons for performing amniocentesis is an abnormal alpha-
fetoprotein (AFP) test. Because this test has a high false-positive rate, another test such as 
amniocentesis is recommended whenever the AFP levels fall outside the normal range 
(Sepulveda et al.,1995). 
3.3 Laboratory considerations for amniocentesis 
The cells within the amniotic fluid arise from fetal skin, respiratory tract, urinary tract, 
gastrointestinal tract and placenta. After obtained fetal cells, they are put into tissue culture, 
either in flasks or more often on coverslips. After 3 to 7 days of growth, sufficient mitoses 
are present for staining and karyotype analysis. Viable cells in the amniotic fluid are 
cultured and used for karyotyping, and investigation of metabolic and biochemical 
disorders. Uncultured cells may now be used to detect specific chromosome aberrations by 
using chromosome specific probes and fluorescent in situ hybridization (FISH) on 
interphase cells, but complete karyotyping is not yet possible on uncultured cells 
(Pergament,2000). Amniocyte  culture is quite reliable, with failure occurring in less than 1% 
of cases. The culture failure rate increase with falling  gestational age and it seems to occur 
more often in fetal aneuploidy. Chromosomal mosaicism most frequently results from 
postzygotic  nondisjunction but can also occur from meiotic errors with trisomic rescue. The 
most common etiology is pseudomosaicism where the abnormality is evident in only one of 
several flasks or confined to a single colony on a coverslip. In this case the abnormal cells 
have arisen in vitro, are not present in the fetus, and are not clinically important. 
Alternatively, true fetal mosaicism is rare, occurring in 0,25% of amniocentesis but can be 
clinically important, leading to phenotypic or developmental abnormalities. Maternal cell 
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contamination may cause misdiagnosis, if only maternal cells are examined or mosaicism is 
suspected. The rate of maternal cell contamination is 1-3 per 1000 cases, but this figure 
should probably be doubled as maternal cell contamination is only detected when the fetus 
is male (Tepperberg  et al.,2001). A large study (Welch et al.,2006) sought to relate the 
frequency of maternal cell contamination in amniotic fluid samples that were submitted to a 
single laboratory for cytogenetic analysis to the experience and training of the physician 
who performed the amniocentesis.  
Fluorescence in situ hybridization (FISH) probes are relatively short fluorescently labeled DNA  
sequences that are hybridized to a known location on a specific chromosome and allow for 
determination of the number and location of specific DNA sequences. Presently, it is suggested 
that FISH analysis not be used as a primary screening test on all genetic amniocenteses because 
of its inability to detect structural rearrangements, mosaicism, markers, and uncommon 
trisomies. Because all abnormalities would be detectable by tissue culture, FISH analysis is not 
cost effective. Presently, most laboratories use FISH to offer quick reassurance to patients with 
an unusually high degree of anxiety or to test fetuses at the highest risk, such as those with 
ultrasound anomalies. It is also beneficial in cases where rapid results are crucial to subsequent 
management, such as advanced gestational age (Sawa et al., 2001). 
3.4 Complications 
Amniocentesis is not without maternal and fetal complications and should be undertaken 
with due regard to the risks involved. 
3.4.1 Maternal 
The risk of intervention for the mother is minimal. The risk of an amnionitis after 
amniocentesis is less than 0,1% and the risk of a severe maternal infection reaches 0.03%-0.09% 
(Wurster et al.,1982). In a retrospective survey of 358 consecutive amniocentesis ( Pergament, 
2000) there were two patients who developed amniotic fluid peritonism and one with minor 
intraperitoneal bleeding. Amniocentesis is not associated with severe pregnancy complications 
such as placental abruption or placenta praevia. On the other hand after amniocentesis there is 
an increased risk of complications related to amniotic cavity, membranes and hypotonic 
uterine dysfunction (Cederholm et al.,2003).Feto-maternal hemorrhage  occurs during 
amniocentesis in one out of six women, and may therefore theoretically give rise to subsequent 
isoimmunisation. In a prospective cohort study (Tabor et al.,1987) the immunization rate was 
1.4%. The observed 1.4% immunization rate is not different from the spontaneous 
immunization rate. In spite of these findings, and since Rh-immune serum globulin is 
apparently harmless to the fetus and mother, its use is recommended in nonsensitized Rh-
negative mothers after amniocentesis Practice differs between countries regarding whether 
this recommendation is followed or not. In American  controlled study anxiety and depression 
varied similarly in women having amniocentesis and in control women. However, among 
women having amniocentesis due to advanced maternal age, the anxiety level was increased 
while awaiting the results of the test (Phipps et al.,2005). 
3.4.2 Fetal 
The major risk of mid-trimester amniocentesis is fetal loss. Two types of loss should be 
considered: (1) total pregnancy loss rate postprocedure, which includes both background 
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pregnancy loss for that gestational age and procedure-related loss, and (2) procedure related 
pregnancy loss. The total post-amniocentesis loss rates are derived from studies of 
populations of pregnant women who underwent amniocentesis, with a control group 
consisting of populations of pregnant women who had another procedure. The 
amniocentesis-related pregnancy loss rates are derived from studies of pregnant women 
who had amniocentesis compared with a “no procedure” control group. A  study published 
by Eddleman et al. suggests that the procedural loss rate of amniocentesis may be much 
smaller than previously reported, further challenging the indications for invasive testing in 
the context of a traditional “risk-benefit” ratio (Eddleman et al.,2006). Although the 
committee agrees that it is timely to re-evaluate this issue, it is believed Eddleman’s 
conclusion that the rate of miscarriage due to amniocentesis of 0.06% (1/1600) is misleading 
and should be interpreted with caution. The study is based on a secondary analysis of data 
from the “First and Second Trimester Evaluation of Risk for Aneuploidy” (FASTER) trial, 
the primary goal of which was to compare first and second trimester noninvasive prenatal 
genetic screening methods. Among the 35 003 women enrolled the rate of spontaneous fetal 
loss prior to 24 weeks’ gestation in the study group was 1%, not statistically different from 
the control group rate of 0.94%. The risk of miscarriage due to amniocentesis was reported 
to be the difference between these two rates, which was 0.06%. Letters to the editor have 
criticized the FASTER conclusion. Nadel (Nadel,2007) concluded that the likelihood of 
amniocentesis resulting in the loss of a euploid fetus is less than 0.5% .Smith (Smith,2007) 
commented that the methods used to include or exclude pregnancy termination patients 
resulted in the paradox of a statistically significant increase in spontaneous abortion for 
women not having amniocentesis with a positive screen and women who were aged 35 
years or over. The lowest rate of risk for genetic amniocentesis derived from the literature is 
about 1 in 300 (Wilson,2007). In counseling patients prior to amniocentesis, it is important to 
convey to patients that at their stage of pregnancy there is still a background pregnancy loss 
rate, and that amniocentesis will contribute an additional procedure related loss rate. The 
notion of background population or individual loss rate is important, as the patient will not 
be able to determine whether her pregnancy loss was “background” or 
“procedural.”Counselling should provide a woman with the total pregnancy loss rate to 
enable her to fully understand the possible sequelae of her decision. Individual procedural 
risks may be required for counseling because of the real variables that contribute to the 
population or individual background risk. 
A. Patient factors 
1. Maternal age/ paternal age (Kleinhaus et al.,2006) 
2. Past reproductive history 
3. Pre-existing maternal conditions (diabetes, hypertension, infertility, autoimmune)  
4. Pregnancy/uterine (assisted reproductive techniques, vaginal bleeding, uterine 
fibroids, placental location, amniotic fluid loss, oligohydramnios, retro chorionic 
hematoma, single vs. multiple gestations) 
5. Screening methodology 
i. timing (first trimester, second trimester, first and second trimester) 
ii. technique (ultrasound alone, biochemistry, biochemistry and ultrasound, nuchal 
translucency +/- biochemistry, single or multiple soft markers or congenital 
anomalies) 
www.intechopen.com
 
Invasive Prenatal Diagnosis 
 
13 
B. Procedure factors  
1. Amniocentesis needle size variation 
2. Operator experience 
3. Ultrasound guided (freehand; needle guide) 
4. Uterine/placental location 
5. Maternal BMI 
C. Postprocedure factors 
1. Rest for 24 hours or normal activity (no evidence-based comparisons available) 
2. Complications (ruptured membranes, infection) 
Increasing maternal and paternal age are significantly associated with spontaneous 
abortion, independent of amniocentesis and multiple other factors (Kleinhaus et al.,2006). 
Also pre-existing maternal conditions, as well as assisted reproductive techniques and 
multiple gestations are “per se“ risk factors for increase fetal loss (Bianco et al.,2006). 
Amniocentesis before 14 weeks gestation has an adverse effect on fetal loss (Alfirević et 
al.,2007). Rupture of membranes is an uncommon complication of genetic amniocentesis. 
Theoretically, a thin needle may have both advantages and disadvantages for fetal loss. One 
would expect a thin needle to cause a smaller hole in the membranes and to be less 
traumatic, thereby decreasing the risk of amniotic fluid leakage and feto-maternal 
hemorrhage. On the other hand, a thin needle increases the procedure time, and increased 
sampling time might be associated with an increased risk of chorio-amnionitis and fetal loss 
(Weiner,1991). It seems reasonable to assume the fetal loss to be lower if the operator has 
performed a large number of invasive procedures than if he/she is inexperienced. 
(Milunsky,2010). The number of annual procedures needed for amniocentesis to be safe is 
not known, and the recommendation of at least 150 amniocenteses per year is not based on 
scientific evidence. There is indirect evidence from nonrandomized studies that ultrasound 
guided amniocentesis is safer than blind amniocentesis, because feto-maternal hemorrhage 
occurs less often if the procedure is performed under ultrasound guidance than if it is done 
blindly  and feto-maternal hemorrhage may be associated with an increased risk of fetal loss 
(Papantoniou et al.,2001). In the study by Weiner and colleagues, there was some evidence 
that the rate of fetal loss after amniocentesis increased with the number of needle insertions. 
On the other hand they did not find increased fetal  loss after transplacental passage of the 
amniocentesis needle than after non-transplacental passage. Possibly, the most important 
thing is to perform the procedure as atraumatically as possible. Therefore, the puncture site 
that gives easiest access to a pocket of free fluid should be chosen. If the placenta can be 
easily avoided, it is probably wise to avoid it. Whether the amount of amniotic fluid 
removed has any effect on fetal loss rates is not known, but it is probably wise to remove as 
little as possible (usually 15-20 ml is enough to obtain a diagnosis). Spontaneous reseal of 
ruptured membranes after genetic amniocentesis can occur with conservative management 
and end with a favorable pregnancy outcome (Phupong & Ultchaswadi,2006). 
The Table 1 summarizes the recent published reports (randomized controlled trials and 
cohort studies with or without a control group; the control group may have no procedure or 
an alternative procedure), showing a range of post mid-trimester amniocentesis losses of 
0.75 to 2,1% .The FASTER study pregnancy loss difference (amniocentesis; no 
amniocentesis) is a clear outlier within these controlled study groups and reflects that this 
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study’s method of analysis underestimated the procedure-related pregnancy loss rate 
following mid-trimester amniocentesis by excluding the terminated pregnancies in the 
amniocentesis group, resulting in a lower intrinsic rate of pregnancy loss for this group than 
for the control group. 
In conclusion there is no single percentage (or odds ratio) that can be quoted as the risk of 
pregnancy loss following midtrimester amniocentesis in singleton pregnancies. The risks 
unique to the individual and is  based on multiple variables, as summarized in this opinion. 
The best estimate range to consider for the increased rate of pregnancy loss attributable to 
amniocentesis is 0.6% to 1.0% but may be as low as 0.19% or as high as 1.53% on the basis of 
the confidence intervals  seen in the various studies.  
The fetal loss rate in multiple gestations has not been estimated in a controlled trial and is 
difficult to determine due to the increased miscarriage rate per se in twin pregnancies. An 
increased post-amniocentesis abortion rate in multiple gestations may be expected, since 
most operators use more than one needle insertion, a variable associated with an increased 
fetal loss rate (Toth-Pal et al., 2004). In the largest Israel study fetal loss among bichorionic 
twin gestations undergoing genetic amniocentesis was compare with singletons undergoing 
the procedure and untested twins. Fetal loss was 2,73% in the first group, compared to 0,6% 
and 0,63% in the other two groups. It may thus be concluded  that the risk of early fetal loss 
is apparently higher in twins undergoing amniocentesis than in untested twins or tested 
singletons. These data can be of value in counseling parents of twins because of the 
increased number of gestations resulting from fertility programs and the elevated risk of 
chromosomal abnormalities in twin pregnancies (Yukobowich et al.,2001). Whether 
amniocentesis in twin pregnancies should be performed by using one or two needle 
insertions remains to be shown. A single needle insertion could reduce the abortion risk, but 
may on the other hand create the problems of amniotic band syndrome or a mono-amniotic 
twin pregnancy, or give rise to cytogenetic problems (Wapner et al.,1993). 
Considering perinatal mortality et morbidity, amniocentesis does not affect the preterm 
birth rate, the stillbirth rate or the perinatal mortality rate. This procedure does not affect 
neither the mean birth weight. In early experience with amniocentesis, needle puncture of 
the fetus was reported in 0,1% to 0,3% of cases (Karp & Hayden, 1977) and was associated 
with fetal exsanguinations (Young et al., 1977), intestinal atresia (Swift et al., 1979), 
uniocular blindess, porencephalic cysts, peripheral nerve damage and intestinal atresia 
(Karp & Hayden,1977) Continuous use of ultrasound to guide the needle minimizes needle 
puncture of the fetus and in the hands of experienced operators those are extremely rare 
complications. The British study ( Medical Research Study, 1978) also found an increase in 
postural deformities such as talipes and congenital dislocation of the hip. The possible 
mechanism of this deformity is compression due to olygohydramnios or tissue injury from 
the amniocentesis needle. This study was criticized for biases in the selection of the control 
patients who were younger, had less parity, entered later in the gestation in the study and 
some of the matched controls were replaced with other controls.No long-term adverse 
effects have been demonstrated in children undergoing amniocentesis. Finegan and 
colleagues (Baird et al.,1994) showed that  the offspring of women who had had 
amniocentesis were no more likely than controls to have a registrable disability (such as 
hearing disabilities, learning difficulties, visual problems, and limb anomalies) during 
childhood and adolescence. At the ages of 4 and 7 years, there was no difference between 
the two groups regarding child social competence, behaviour, growth and health. The 
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results suggest that the wide range of developmental and behavioural variables studied is 
not influenced by removal of amniotic fluid in the mid-trimester.  
 
 
RCT: Randomized controlled trial; C: cohort/case–control study; CVS: chorionic villus sampling (TA: 
transabdominal; TC: transcervical); EA: early amniocentesis; 
RR: relative risk; CI: confidence interval; NS: non-significant difference. 
* Study group: women 20–34 years of age having amniocentesis for increased risk of aneuploidy or 
maternal infection; control group: women 20–34 years of age at 
low risk but having amniocentesis 
 
Table 1. Summary of studies with mid-trimester amniocentesis population 
3.5 Early amniocentesis 
The desire for a first-trimester diagnosis stimulated interest in the feasibility of performing 
amniocentesis under 15 weeks gestation including first trimester. The major advantage of 
early amniocentesis (9 to 14 weeks’ gestation) is that results are known much more earlier. 
This procedure which was introduced in the late 1980s, is technically the same as a ’late’ 
procedure except that less amniotic fluid is removed. The 15ml amniotic fluid  at this week 
of pregnancy is a significant amount, while the extremities are in a critical period for the 
development. Ultrasound needle guidance is considered to be an essential part of the 
procedure because of the relatively small target area. The presence of two separate 
membranes (amnion and chorion) until 15 weeks’ gestation creates an additional technical 
difficulty. Only the amniotic (inner) sac should be aspirated, because the outer sac does not 
contain sufficient numbers of living fetal cells. It has been reported that there is a culture 
failure ranging from o,5-2,5%. The karyotyping success rate may be increased by using filter 
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techniques in which amniotic cells are retained on a filter after aspiration while the rest of 
the amniotic fluid (cell free) is reinjected into the amniotic cavity (Alfirević et al.,2007). 
Fetal complications related to early amniocentesis were expected to be higher than those 
related to mid-trimester amniocentesis because of the higher amount of removed amniotic 
fluid (Johnson et al., 1999). Since a controlled trial has not yet been done, the complications 
following early amniocentesis has been compared to that following chorionic villus 
sampling (CVS) or amniocentesis in week 16-18. To determine the safety and accuracy of 
early amniocentesis, a randomized, multicenter Canadian study (Meier et al.,2005) 
compared the procedure to second-trimester amniocentesis.Among the women in the early 
amniocentesis group, 1% gave birth to infants with a foot anomaly. By comparison, only 
0.1% of those in the second-trimester group gave birth to infants with this deformity a 
proportion similar to that found within the general population.Both the U.K. and Danish 
studies (Tabor et al., 1986) found an increase in respiratory distress syndrome and 
pneumonia in neonates from the mothers who underwent early amniocentesis. It may be 
that altered amniotic fluid volume after amniocentesis or subsequent chronic amniotic 
fluid leakage interferes with normal lung development and lung structure at term, thus 
giving rise to pulmonary hypoplasia and consequently to RDS in the newborn. Whether 
these antenatal and neonatal changes have any longterm impact on lung development 
remains to be shown. The study, funded by the National Institute of Child Health and 
Human Development (Philip et al.,2004) compared the rate of fetal loss between early 
amniocentesis and CVS. The combined outcome of spontaneous loss before 20 weeks and 
procedure-related termination occurred slightly more often after amniocentesis than after 
CVS, with risk most increased when amniocentesis was performed during week 13. In 
addition, incidence of talipes equinovarus (clubfoot) was fourfold higher after 
amniocentesis than after CVS , again, most cases occurred when amniocentesis was 
performed during week 13. .  
Early amniocentesis appears to be as accurate as CVS and mid-trimester amniocentesis. 
Amniocentesis at 13 weeks gestation carries a significantly increase risk of talipes 
equinovarus and respiratory illness compared with CVS and mid-trimester amniocentesis 
and also suggests an increase in early, unintended pregnancy loss. The safety of 
amniocentesis before 14 weeks gestation is uncertain. Until its safety can be ensured, it is 
best to delay routine sampling until week 15 or 16 of pregnancy. 
4. Cordocentesis 
Cordocentesis is an invasive method of obtaining fetal blood from umbilical cord  using 
transabdominal approach. This method first described in 1983 by Daffos and coworkers 
offers advantage in efficacy and safety over the fetoscopic methods previously used to 
obtain fetal blood and nowdays almost completely abandoned  (Daffos et al.,1985). The 
main target for obtaining fetal blood is the umbilical vein. Other possible targets for fetal 
blood sampling are fetal heart ventricles and the intrahepatic tract of the umbilical vein 
(Antsaklis et al., 1992) 
4.1 Timing and technique 
Depending on the indication, cordocentesis can be performed from about 18 completed 
weeks of gestation until the end of the pregnancy. When imaging and placental conditions 
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are optimal, it can be done as early as 15 completed weeks. It is usually performed on an 
ambulatory basis. It requires a high-resolution ultrasound scanner, an experienced team and 
a laboratory specializing in fetal blood analysis (Sirirchotiyakul et al.,2000). The most 
favorable puncture site is the placental insertion of the umbilical cord, as the cord is the least 
mobile at that location. A 20-22 gauge needle is used. A stable needle is important, 
especially with the posterior placenta, so that the needle will not bend on the relatively long 
path to the umbilical cord insertion (Ghezzi et al.,2001). Blood is drawn from the umbilical 
vein with a 1ml syringe. Blood samples must be immediately examined to identify to purity 
of the sample and the results of the analysis can be significantly altered in case it has been 
contamined by maternal blood or amniotic fluid. A free loop of umbilical cord or the fetal 
insertion of the cord can also be used for puncture. Intra-abdominal puncture of the 
umbilical vein is yet another option. It is most difficult to puncture a free loop of umbilical 
cord. Attempts to puncture free loops often result in the cord being pushed away by the 
needle (Liaou et al.,2006). Besides the large-caliber vein, it is also possible to sample blood 
from one of the two smaller-caliber umbilical arteries. This procedure, however, carries a 
risk of vasospasm with subsequent fetal bradycardia and/or profuse afterbleedind and 
therefore puncture of the umbilical vein is always preferred. Fetal heart is an alternative 
sampling site and this technique can be used when access to the fetal circulation  must be 
obtained at gestational age less than 17-18 weeks gestation or if an emergency blood 
transfusion is required. 
4.2 Indications 
Indications for cordocentesis have changed regarded to past decade. In fact the list is shorter 
than a decade ago because the noninvasive methods have rendered  cordocentesis less 
important. However, some specific metabolic, hematologic or gene disorders are still 
testable only by fetal blood sampling. Cordocentesis is most commonly used for rapid fetal 
karyotyping (Shah et al., 1990). This is done in cases with ambiguous chromosomal findings 
from amniotic cell culture or CVS. The results can be obtained in 48-72 hours by leukocyte 
culture of the fetal sampled blood. This advantage of rapid karyotyping can also be used 
when ultrasound reveals an abnormality that is associated with chromosome disorders or in 
cases of an abnormal triple test. On the other hand some essentials blood tests are replaced 
by amniocentesis due to PCR techniques for gene amplification and the emergence of many 
new genetic markers. Various fetal infections can be diagnosed in the fetal blood: rubella, 
cytomegalovirus, toxoplasmosis, varicella and parvovirus B19 (Valente et al., 1994). For 
detection a fetal infection cordocentesis is not performed before 22 weeks of gestation 
because IgM antibodies occur in fetal blood after 20 weeks of gestation. Various blood 
diseases can be diagnosed using cordocentesis: hemoglobinopathies, coagulopathies, 
immune deficiencies and trombocytopenias (Burrows and Kelton, 1993). Determination of 
the platelet count in congenital thrombocytopenias provides important information on the 
intrauterine risk to the fetus which is particularly applies to alloimune thrombocytopenia. If 
this disease is confirmed intrauterine therapy with platelets should be performed to avoid 
fetal cerebral hemorrhage. In disorders that can lead to severe fetal anemia as a result of 
hemolysis (Rh or Kell alloimmunisation, parvovirus B19 infection) cordocentesis can 
directly determine the degree of anemia and provide a specific basis for planning an 
intrauterine transfusion (Bowman, 1991). The use of Doppler  peak velocity to assess the 
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degree of fetal anemia reduce the need for fetal blood sampling. However, cordocentesis is 
always indicated when history, maternal titers or MCA Doppler  show a risk of anemia. 
Correlation between biophysical profile scoring (BPS) and fetal PH on cordocentesis, reduce 
percentage of fetal blood sampling in the determination of fetal blood gases and acid-base 
status, because BPS can be safely use to indicate fetal PH without invasive method. But 
because neither the BPS patterns nor Doppler findings provide clear-cut evidence of fetal 
compromise in all cases, cordocentesis can be a useful adjunct to the noninvasive tests, 
especially in cases of severe growth retardation. In cases with abnormal Doppler flow with a 
normal BPS score, cordocentesis can confirm or exclude chronic fetal asphyxia. 
4.3 Complications 
The overall complication rate of cordocentesis is slightly higher than that of amniocentesis. 
Besides the risk that are the same as for amniocentesis such as: abortion,  membrane rupture 
and chorioamnionitis, there are additional risks that are specific for cordocentesis. Fetal loss 
rate related to cordocentesis  reported to be as high as 6-7% in centers with low experience, 
but in experienced hands the rate is as low as 1-2%. Overall pregnancy loss rate depends 
largely on the fetal condition for which cordocentesis is done. The rate of pregnancy loss is 
worse in cases of fetal anomalies and abnormal karyotype (Tongsong et 
al.,2001).Unfortunately no controlled trials are yet available and it is not quite clear what is 
the fetal loss rate to quote to patients, because most clinical series contain many high risk 
cases such as stated before. The most common complication of cordocentesis is fetal 
bradycardia. The rate of fetal bradycardia reported in literature is 6,6%. In most cases it is 
transient, self-limited and with no long-term concequences. It is related to uterine 
contraction directly at the cord insertion or  fetal movement against the umbilical cord by 
the contraction. Profound or prolonged bradycardia occurs in less than 3% of cases and it is 
associated with umbilical artery vasospasm after puncture of the umbilical cord or tetanic 
uterine contraction, which is rar. Early gestational age and hydrops fetalis correlated 
significantly with the development of bradycardia at cordocentesis. The other risk groups, 
including fetuses with intrauterine growth retardation, the puncture site, and the number of 
puncture attempts did not correlate with fetal bradycardia  (Preis et al.,2004). Transient 
bleeding from the umbilical cord puncture, called the “jet phenomenon” is a relatively 
common, innocuous finding after cordocentesis and it lasts no more than 2 minutes.The 
bleeding from the artery is reported to be longer than that from the vein. Differences among 
centers with respect to bleeding may relate to the size of the needle used and the technique 
employed.Bleeding over 300 seconds or massive hemorrhage occurs less than once per 200 
cordocentesis. When this occurs a viable fetus should be delivered by emergency cesarean 
section. Hematomas of the cord have been observed in pathologic specimens with the 
freehand technique, although most are not associated with adverse sequelae (Kay et 
al.,2011). The incidence of symptomatic cord hematoma  causing significant fetal 
bradycardia is very low. The risk of amnionitis is approximately 1% when the freehand 
technique is used and less than 0.3% when the needle-guided technique is used. Rarely, 
chorioamnionitis can lead to the development of maternal sepsis and adult respiratory 
distress syndrome. 
Maternal complications are also seen. Cordocentesis lasts longer than amniocentesis, so 
the mother will more likely be anxious and have more discomfort. On the other hand, 
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cordocentesis is less uncomfortable than CVS, so the patients will less complain of pain 
and contractions.Acute rupture of membranes and preterm labor are very rare 
complications. 
Fetal-maternal transfusion has been reported after both cordocentesis and amniocentesis, 
especially when the placenta was anterior. It is imperative that Rh-negative women be given 
Rh immunoglobulin after a procedure unless the fetus is known to be Rh-negative or the 
patient is already sensitized (Rujiwetpongstorn et al.,2005) 
The safety of cordocentesis is believed to be both technique-dependent and experience-
dependent. Fewer punctures are reported with the freehand technique, but a lower 
fetal/neonatal loss rate is reported with the needle-guided technique. The rate of bleeding is 
reported to be reduced with the needle-guided technique and with the use of smaller gauge 
needles. Several investigators have found  a greater number of complications among their 
first 30 procedures. 
5. Other invasive diagnostic procedures 
On infrequent occasions, analysis of other fetal tissues may be required. Because they are 
only rarely required, their use is usually confined to only a few regional referral centers in 
hopes of limiting procedural risk. Fetal skin biopsy is indicated for diagnosis of some type of 
genodermatosis or congenital dermoepidermic disorders which is  expected to be lethal in 
short or medium terms. Those disorders are: bullous epidermolysis, anhidrotic ectodermic 
dysplasias, keratinization disorders and pigmentary atopies (Elias et al.,1994). It can also be 
helpful in the workup of fetal mosaicism for some chromosomes, such as 22 chromososme, 
which are known not to be manifest in fetal blood. Fetal muscle biopsy is used to diagnose 
Duchenne’s muscular dystrophy in a male fetus if DNA testing is not informative (Nevo et 
al.,1999). It can also be used to detect other hereditary myopathies as long as there is some 
clinical family history of these disorders. Fetal liver biopsy was the only means of 
diagnosing fetuses with inborn errors of the urea cycle such as ornithine transcarbamylase 
deficiency, carbamoylphosphate synthetase deficiency and other disorders expressed only 
in the liver such as von Gierke glycogen-storage disease type IA and primary hyperoxaluria 
type I (Haberle et al.,2004). However, most of these conditions are now diagnosable by DNA 
analysis (without the need for histology and enzymatic assays) of cells extracted from either 
chorionic villi or amniocytes. Direct genetic analysis of chorionic villi is feasible, fast and 
specific and can be regarded as the primary choice  for prenatal diagnosis of these rare 
conditions. The procedure which is used more frequent than the previous described is 
aspiration and biochemical analysis of fetal urine for the evaluation of fetal renal function. 
This evaluation is essential in determination of fetuses whose kidneys are not irreversible 
damaged and who will have the benefit from intrauterine derived therapy.The biochemical 
markers that have close relation with the renal function are defined by Na,Cl, beta-2 
microglobuline and osmotic urine (Troyano et al., 2002).Other punctures on fetal tumor 
formations such as teratomas or liquid collections such as pericardiocentesis do not have an 
acceptable justification from a diagnostic point of view, as the echographic evaluation and 
the present application of biophysical methods give an acceptable identification of their 
vascularisation and origin, including those of suspicious neoplasm. 
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6. Conclusion 
More than 40-year history of invasive procedures has seen a rise and than a fall in the 
degree of invasiveness of the procedures. The decades of invasive diagnostic procedures  
have given us a unique opportunity to study the fetus. They have contributed to our 
understanding of human fetal physiology, metabolism, and disease. However, the 
introduction of non-invasive procedures has diminished the need for some invasive 
procedures, in the first place for cordocentesis. As molecular genetics shrinks the role of 
cordocentesis for prenatal diagnosis of hereditary disease and as cytogenetic techniques 
make inroads that supplant the need for fetal blood sampling to obtain a rapid karyotype, it 
is likely that there will be fewer indications for cordocentesis in the next decade. A 
diminished role for cordocentesis will demand further regionalization of care in order for 
some persons to maintain the skill and further the knowledge base of normal fetal 
physiology and fetal disease. On the other hand amniocentesis still remains the gold 
standard for karyotyping, especially now that rapid diagnostic methods are available. Will 
nowdays invasive proceduers suffer the same fate as fetoscopy—here one day, gone 
another—or will the indications for them gradually be refined, limiting its practice to 
situations not suitable for noninvasive fetal testing remains to be shown. Invasive 
procedures may become obsolete when reliable non-invasive prenatal diagnosis becomes 
available. 
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useful resource to practitioners and scientists in fetal medicine.
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